Citations

Clear

499 citation(s) found for "Tracy, PB".

Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study
Boorjian, Stephen A. , Canter, Daniel , Ogan, Kenneth , Downs, Tracy M. , Gomella, Leonard G. , Svatek, Robert S. , Bivalacqua, Trinity J. , Grubb, Robert L. , Krupski, Tracey L. , Inman, Brant A. , Milowsky, Matthew I. , Boyd, Alan , Treasure, F. Peter, Gregory, Gillian , Sawutz, David G., Parker, Nigel, Dinney, Colin P. , Canter, Daniel J, Karsh, Lawrence I, Woods, Michael E. , Yla-Herttuala, Seppo, Parker, Nigel R, Dinney, Colin P N, Inman, Brant A , Shore, Neal D. , Karsh, Lawrence Ivan , Kamat, Ashish M. , Lotan, Yair , Lerner, Seth P. , Ylä-Herttuala, Seppo

Mayo Clinic

Journal of Clinical Oncology | August 23, 2017 | Volume: 35 | Issue: 30 | Pages: 3410-3416

10.1200/jco.2017.72.3064 | PMID 28834453 Get It

Purpose Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd–IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials.gov identifier: NCT01687244), 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical rAd–IFNα/Syn3 (randomly assigned 1:1 to 1 × 10 11 viral particles (vp)/mL or 3 × 10 11 vp/mL). Patients who responded at months 3, 6, and 9 were retreated at months 4, 7, and 10. The primary end point was 12-month HG recurrence-free survival (RFS). All patients who received at least one dose were included in efficacy and safety analyses. Results Forty patients received rAd–IFNα/Syn3 (1 × 10 11 vp/mL, n = 21; 3 × 10 11 vp/mL, n = 19) between November 5, 2012, and April 8, 2015. Fourteen patients (35.0%; 90% CI, 22.6% to 49.2%) remained free of HG recurrence 12 months after initial treatment. Comparable 12-month HG RFS was noted for both doses. Of these 14 patients, two experienced recurrence at 21 and 28 months, respectively, after treatment initiation, and one died as a result of an upper tract tumor at 17 months without a recurrence. rAd–IFNα/Syn3 was well tolerated; no grade four or five adverse events (AEs) occurred, and no patient discontinued treatment because of an adverse event. The most frequently reported drug-related AEs were micturition urgency (n = 16; 40%), dysuria (n = 16; 40%), fatigue (n = 13; 32.5%), pollakiuria (n = 11; 28%), and hematuria and nocturia (n = 10 each; 25%). Conclusion rAd—IFNα/Syn3 was well tolerated. It demonstrated promising efficacy for patients with HG NMIBC after BCG therapy who were unable or unwilling to undergo radical cystectomy.
Super-response to cardiac resynchronization therapy reduces appropriate implantable cardioverter defibrillator therapy
Killu, Ammar M. , Mazo, Anna, Grupper, Avishay , Madhavan, Malini , Webster, Tracy L., Brooke, Kelly L., Hodge, David O. , Asirvatham, Samuel J. , Friedman, Paul A. , Glikson, Michael , Cha, Yong‐Mei , Webster, Tracy, Asirvatham, Samuel J , Glikson, Michael

Mayo Clinic

EP Europace | August 4, 2017 | Volume: 20 | Issue: 8 | Pages: 1303-1311

10.1093/europace/eux235 | PMID 29016821 Get It

Abstract 712: Detection of lung cancer by assay of novel methylated DNA markers in plasma
Allawi, Hatim T. , Giakoumopoulos, Maria , Flietner, Evan, Oliphant, Austin, Volkmann, Carla J., Aizenstein, Brian, Sander, Tamara, Eckmayer, Drew, Strong, Ashley Poenitzsch, Gray, Melissa A. , Yab, Tracy C. , Taylor, William C., Midthun, David E. , Ahlquist, David A. , Lidgard, Graham P. , Strong, Ashley M. Poenitzsch , Berger, Barry M. , Mahoney, Douglas W. , Kisiel, John B.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 712-712

10.1158/1538-7445.am2017-712 Get It

Abstract Purpose: Lung cancer is the leading cause of cancer deaths worldwide. Most present symptomatically at late stage with high lethality. Early detection reduces mortality but accurate and readily accessible tools for population screening are limited. By whole methylome sequencing, we have identified novel methylated DNA markers (MDMs) for lung cancer in tissue (Giakoumopoulos et al. ASCO 2016). Using top candidate MDMs in the present study, we now explore their clinical accuracy for lung cancer detection when assayed from plasma. Experimental Procedures: Archival plasmas from two independent study groups were tested in blinded fashion. Lung cancer cases and controls (apparently healthy smokers) for each group were balanced on age and sex (Group 1: 64 cases, 231 controls; Group 2: 23 cases, 80 controls). Using multiplex PCR followed by QuARTS (Quantitative Allele-Specific Real-time Target and Signal amplification) assay, a post-bisulfite quantification of MDMs on DNA extracted from plasma was performed. We selected 31 MDM candidates for initial evaluation in Group 1 (1 ml plasma/patient); top individual MDMs were subsequently tested in Group 2 to identify optimal MDM panels for lung cancer detection (2 ml/patient). Results: From Group 1 analyses, 13 high performance MDMs were selected for further testing (CYP26C1, SOBP, SUCLG2, SHOX2, ZDHHC1, NFIX, FLJ45983, HOXA9, B3GALT6, ZNF781, SP9, BARX1, EMX1) with individual areas under the receiver operator curve (AUCs) ranging from 0.593 to 0.939. Discrimination by individual MDMs was corroborated in Group 2 in which data was analyzed using two methods: a logistic regression fit and a regression partition tree approach. The logistic fit model identified a 4-marker panel (ZNF781, BARX1, EMX1, and SOBP) with an AUC of 0.96 and an overall sensitivity of 91% and 90% specificity. Analysis of the data using a regression partition tree approach identified 4 markers (ZNF781, BARX1, EMX1, and HOXA9) with AUC of 0.93 and an overall sensitivity of 96% and specificity of 94%. For both approaches, B3GALT6 was used as a standardizing marker of total DNA input. Conclusion: A panel of MDMs assayed in plasma achieved high sensitivity and specificity for all types of lung cancer. Further clinical evaluation and validation of this promising panel in larger patient groups are clearly indicated. Citation Format: Hatim T. Allawi, Maria Giakoumopoulos, Evan Flietner, Austin Oliphant, Carla Volkmann, Brian Aizenstein, Tamara Sander, Drew Eckmayer, Ashley Poenitzsch Strong, Melissa Gray, Barry Berger, Tracy Yab, William Taylor, Douglas Mahoney, John B. Kisiel, David E. Midthun, David A. Ahlquist, Graham P. Lidgard. Detection of lung cancer by assay of novel methylated DNA markers in plasma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 712. doi:10.1158/1538-7445.AM2017-712
A Comparison of Facial Protection and the Incidence of Head, Neck, and Facial Injuries in Junior a Hockey Players
Smith, Aynsley M., Malo-Ortiguera, Susan A., Fischer, Tracy L., Stuart, Michael J. , Larson, Dirk R.

Mayo Clinic

The American Journal of Sports Medicine | July 19, 2017 | Volume: 30 | Issue: 1 | Pages: 39-44

10.1177/03635465020300012001 | PMID 11798994 Get It

A cohort of 282 elite amateur ice hockey players were analyzed to 1) record the number, type, location, and severity of head, neck, and facial injuries sustained during games; 2) examine the relationship between injuries and the type of facial protection (none, partial, or full) according to individual playing time; and 3) determine whether full or partial facial protection is associated with an increased incidence of concussions, eye injuries, and neck injuries. Fifty-two injuries (158.9 per 1000 player-game hours) occurred in players wearing no facial protection, 45 (73.5 per 1000 player-game hours) in players wearing partial facial protection (half shield), and 16 (23.2 per 1000 player-game hours) in players wearing full facial protection (full cage or shield). Players wearing no protection were injured at a rate more than twice that of players wearing partial protection and almost seven times higher than those wearing full protection. Concussions occurred in four players wearing no protection, five players wearing partial protection, and two players wearing full protection; these differences were not significant. The risk of eye injury was 4.7 times greater for players wearing no protection compared with those wearing partial protection. No eye or neck injuries occurred in players wearing full protection. This study demonstrates that both full and partial facial protection significantly reduce injuries to the eye and face without increasing neck injuries and concussions.
Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci
Glubb, Dylan M. , Group, the AGO Study, Johnatty, Sharon E. , Quinn, Michael C. , O’Mara, Tracy A. , Gao, Bo , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vergote, Ignace , Beeghly‐Fadiel, Alicia, Benı́tez, Javier , García, María J. , Goodman, Marc T. , Thompson, Pamela J., Dörk, Thilo , Modungo, Francesmary, Moysich, Kirsten B. , Heitz, Florian , Pfisterer, Jacobus , Hillemanns, Peter , Lester, Jenny, Goode, Ellen L. , Cunningham, Julie M. , McCauley, Bryan M. , Jensen, Allan , Schildkraut, Joellen M. , Terry, Kathryn L. , Salvesen, Helga B., Webb, Penny M., Grant, Peter J. , Moffitt, Melissa , Høgdall, Claus , Paul, James, Bernardini, Marcus Q. , Tone, Alicia , Huntsman, David, Woo, Michelle, Group, AOCS, DeFazio, Anna , Kennedy, Catherine J. , MacGregor, Stuart , Chenevix‐Trench, Georgia , Webb, Penelope M. , Bowtell, David D.L. , Lambrechts, Diether , Winham, Stacey J. , Fazio, Anna de , Group, the AGO Study, Tyrer, Jonathan P. , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Dürst, Matthias , Bois, Andreas du , Karlan, Beth Y. , Larson, Melissa C. , Kjær, Susanne K. , Berchuck, Andrew , Cramer, Daniel W. , Bjørge, Line , Webb, Penny M., Pejovic, Tanja B. , Høgdall, Estrid , Glasspool, Rosalind , Group, AOCS, Pharoah, Paul D.P. , Dörk, Thilo , Lambrechts, Diether , Webb, Penelope M , Hillemanns, Peter , Jensen, Allan , Moysich, Kirsten , Kennedy, Catherine J , O'Mara, Tracy A , Heitz, Florian , Lambrechts, Diether , Quinn, Michael C J , MacGregor, Stuart , Benitez, Javier , Chenevix-Trench, Georgia , Høgdall, Claus K , Bowtell, David D , Goodman, Marc T

Mayo Clinic

Oncotarget | June 15, 2017 | Volume: 8 | Issue: 39 | Pages: 64670-64684

10.18632/oncotarget.18501 | PMID 29029385 Get It

CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA
Nayak, Lakshmi , Ferreri, Andrés J.M. , Batlevi, Connie Lee , Batchelor, Tracy T. , Rubenstein, James L. , Johnston, Patrick B. , Ramchandren, Radhakrishnan , Soussain, Carole , Becker, Kevin, Illerhaus, Gerald , Herrera, Alex F. , Masood, Aisha, IWAMOTO, FABIO MASSAITI , Santoro, Armando , Singer, Samuel , Drappatz, Jan , Witzens‐Harig, Mathias , Shipp, Margaret Ann

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 420-421

10.1002/hon.2440_2 Get It

Evaluation of Testing of Acute Leukemia Samples: Survey Result From the College of American Pathologists
George, Tracy I. , Tworek, Joseph A., Thomas, Nicole , Fatheree, Lisa A., Souers, Rhona J., Nakhleh, Raouf E. , Arber, Daniel A. , George, Tracy I

Mayo Clinic

Archives of Pathology & Laboratory Medicine | May 24, 2017 | Volume: 141 | Issue: 8 | Pages: 1101-1106

10.5858/arpa.2016-0398-cp | PMID 28537804 Get It

Context.— The classification and prognosis determination in acute leukemia (AL) are complex and it is unclear what testing is being performed in practice. Objective.— To survey physicians describing their current practice of test ordering in the diagnosis of AL. Design.— In anticipation of a guideline by the College of American Pathologists (CAP) and the American Society for Hematology on laboratory testing needed for the initial workup of AL, a baseline survey was designed by an expert panel from CAP. Members of professional societies were asked to describe their current practice of test ordering. Results.— Two hundred ninety-four responses were received with 258 respondents analyzed after the first qualifying survey question regarding initial diagnosis of AL. One hundred seventy-six of 249 respondents (70.7%) were board-certified hematopathologists. Flow cytometry and karyotype analysis were routinely performed for acute myeloid leukemia (AML) (99.1% [232 of 234] and 96.2% [225 of 234], respectively) and acute lymphoblastic leukemia (ALL) (98.3% [229 of 233] and 96.6% [225 of 233], respectively). In addition, fluorescence in situ hybridization studies were routinely performed by 81.2% (190 of 234) of respondents for AML and 85.0% (198 of 233) of respondents for ALL; other molecular studies were performed by 78.2% (183) for AML and 54.9% (128) for ALL; immunohistochemistry by 44.9% (105) for AML and 47.6% (111) for ALL; and cytochemistry by 24.8% (58) for AML and 14.2% (33) for ALL. Conclusions.— While flow cytometry and karyotyping are routinely reported as being performed for the diagnosis of AL, there is marked variation in the reporting of testing patterns for other genetic studies, immunohistochemistry, and cytochemistry.
GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer
Robinson, Jessica , Tzou, Katherine S., Parker, Alexander S. , Wu, Kevin J. , Hilton, Tracy, Pisansky, Thomas M. , Peterson, Jennifer , Vallow, Laura A., Buskirk, Steven J., Hilton, Tracy W, Schild, Steven E. , Peterson, Jennifer L., Heckman, Michael G.

Mayo Clinic

The British Journal of Radiology | May 9, 2017 | Volume: 90 | Issue: 1075 | Pages: No page available

10.1259/bjr.20170174 | PMID 28486040 Get It

Objective: High GATA2 expression has been associated with an increased risk of poor clinical outcomes after radical prostatectomy; however, this has not been studied in relation to risk of biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer after radical prostatectomy. Our aim was to evaluate the association between protein expression levels of GATA2 in primary prostate cancer tumour samples and the risk of BCR after SRT. Methods: 109 males who were treated with SRT were included. The percentage of cells with nuclear staining and GATA2 staining intensity were both measured. These two measures were multiplied together to obtain a GATA2 H-score (range 0–12) which was our primary GATA2 staining measure. Results: In unadjusted analysis, the risk of BCR was higher for patients with a GATA2 H-score >4 (hazard ratio = 2.04, p = 0.033). In multivariable analysis adjusting for SRT dose, pre-SRT PSA, pathological tumour stage and Gleason score, this association weakened substantially (hazard ratio = 1.45, p = 0.31). This lack of an independent association with BCR appears to be the result of correlations between GATA2 H-score >4 and higher pre-SRT PSA (p = 0.021), higher Gleason score (p = 0.044) and more severe pathological tumour stage (p = 0.068). Conclusion: Higher levels of GATA2 expression appear to be a marker of prostate cancer severity; however, these do not provide independent prognostic information regarding BCR beyond that of validated clinicopathological risk factors. Advances in knowledge: A higher GATA2 expression level appears to be correlated with known measures of prostate cancer severity and therefore is likely not an independent marker of outcome after SRT.
269 Cardiac resynchronization therapy does not reduce the incidence of ventricular arrhythmias
Lin, Grace , Brady, Peter A. , Webster, Tracy L., Rea, Robert F., Hammill, Stephen C., Hayes, David L.

Mayo Clinic

EP Europace | April 14, 2017 | Volume: 7 | Issue: Supplement_1 | Pages: 64-65

10.1016/eupace/7.supplement_1.64-b Get It

The effect of acute maximal exercise on postexercise hemodynamics and central arterial stiffness in obese and normal-weight individuals
Bunsawat, Kanokwan , Ranadive, Sushant M. , Yan, Huimin , Kappus, Rebecca M. , Lane‐Cordova, Abbi D. , Fernhall, Bo , Baynard, Tracy , Ranadive, Sushant

Mayo Clinic

Physiological Reports | March 31, 2017 | Volume: 5 | Issue: 7 | Pages: e13226

10.14814/phy2.13226 | PMID 28364031 Get It